Penumbra Inc. (PEN)

142.34
0.20 0.14
NYSE : Health Technology
Prev Close 142.54
Open 142.37
Day Low/High 140.21 / 144.47
52 Wk Low/High 82.55 / 167.35
Volume 284.24K
Avg Volume 329.10K
Exchange NYSE
Shares Outstanding 34.38M
Market Cap 4.68B
EPS 0.10
P/E Ratio 172.34
Div & Yield N.A. (N.A)

Latest News

Penumbra, Inc. Announces Acquisition Of Controlling Interest In MVI Health

Penumbra, Inc. Announces Acquisition Of Controlling Interest In MVI Health

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced it has closed on the acquisition of a controlling interest in its joint venture, MVI Health Inc.

Penumbra Launches Latest Advancements In Stroke Thrombectomy Aspiration Technology

Penumbra Launches Latest Advancements In Stroke Thrombectomy Aspiration Technology

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.

Penumbra, Inc. Announces Participation At Upcoming Investor Conferences

Penumbra, Inc. Announces Participation At Upcoming Investor Conferences

ALAMEDA, Calif., Aug.

Penumbra, Inc. Reports Second Quarter 2018 Financial Results

Penumbra, Inc. Reports Second Quarter 2018 Financial Results

ALAMEDA, Calif., Aug.

Penumbra, Inc. To Present At The Canaccord Genuity 38th Annual Growth Conference

Penumbra, Inc. To Present At The Canaccord Genuity 38th Annual Growth Conference

ALAMEDA, Calif., July 19, 2018 /PRNewswire/ -- Penumbra, Inc.

Penumbra, Inc. Schedules Second Quarter 2018 Earnings Release And Conference Call For August 7, 2018

Penumbra, Inc. Schedules Second Quarter 2018 Earnings Release And Conference Call For August 7, 2018

ALAMEDA, Calif., July 17, 2018 /PRNewswire/ -- Penumbra, Inc.

Independent Study Reaffirms Penumbra Aspiration As Frontline Thrombectomy Approach For Acute Ischemic Stroke

Independent Study Reaffirms Penumbra Aspiration As Frontline Thrombectomy Approach For Acute Ischemic Stroke

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the presentation of the results of the COMPASS Trial, an independent, prospective, multi-center randomized...

Aspiration First Approach With Penumbra System Demonstrates Favorable Outcomes For Acute Ischemic Stroke

Aspiration First Approach With Penumbra System Demonstrates Favorable Outcomes For Acute Ischemic Stroke

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced results of the company-sponsored PROMISE Study, demonstrating real-world safety and efficacy of the Penumbra...

Penumbra Announces Key Events At International Stroke Conference 2018 Meeting

Penumbra Announces Key Events At International Stroke Conference 2018 Meeting

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced key events at the upcoming International Stroke Conference 2018 meeting (ISC 2018) to be held January 24-26 at...

Penumbra Announces The Formation Of Joint Venture, MVI Health

Penumbra Announces The Formation Of Joint Venture, MVI Health

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced it has entered into a joint venture called MVI Health Inc.

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)

Reports of the death of Facebook, Apple, Amazon, Netflix, Nvidia and Google/Alphabet are greatly exaggerated, says Jim Cramer.

PEN Crosses Above Average Analyst Target

In recent trading, shares of Penumbra Inc have crossed above the average analyst 12-month target price of $89.00, changing hands for $89.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Penumbra Reaches Analyst Target Price

In recent trading, shares of Penumbra Inc have crossed above the average analyst 12-month target price of $87.67, changing hands for $88.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.

There Is a $10 Million Job Now Up for Grabs -- Think You Can Get It?

There Is a $10 Million Job Now Up for Grabs -- Think You Can Get It?

The job scene is good only if you're in the right sector.

Penumbra Reaches Analyst Target Price

In recent trading, shares of Penumbra Inc have crossed above the average analyst 12-month target price of $82.67, changing hands for $83.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Notable Thursday Option Activity: PEN, NTNX, ILG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Penumbra Inc , where a total volume of 3,012 contracts has been traded thus far today, a contract volume which is representative of approximately 301,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 141% of PEN's average daily trading volume over the past month, of 213,550 shares.

Penumbra Announces Key Events At Society Of Interventional Radiology 2017 Meeting

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today announced key events at the upcoming Society of Interventional Radiology 2017 meeting (SIR 2017) to be held March 4-9...

Independent Study Supports Use Of Penumbra Aspiration As Frontline Thrombectomy Therapy For Acute Ischemic Stroke

Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced the presentation of the results of the ASTER Trial, the first independent, prospective, randomized trial comparing the use of...

5 Stocks Setting Up for Big Breakouts

5 Stocks Setting Up for Big Breakouts

Here's how to rake in the gains.

Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years

Jim Cramer's 'Mad Money' Recap: We've Been Afraid of Higher Rates for Years

This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.

Penumbra To Highlight Peripheral Vascular Technologies At AIMsymposium And VEITHsymposium In New York

Penumbra To Highlight Peripheral Vascular Technologies At AIMsymposium And VEITHsymposium In New York

Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced its presence at the upcoming 24 th AIMsymposium ® to be held November 14-17 and the 43 rd VEITHsymposium ® to...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AHP, ARCX, ATNI, HTGC, MGM, PGNX, PGRE, SGMS, SYF, WABC Downgrades: ABDC, ARCC, ARII, BOJA, CTLT, FSM, GEL, H, KMPR, LBTYA, LBTYB, LBTYK, TSCO Initiations: PEN, PSTG Read on to get TheStreet Quant Ratings' detailed report:

Penumbra To Highlight Importance Of Stroke Treatment At Upcoming Patient Awareness Events

Penumbra To Highlight Importance Of Stroke Treatment At Upcoming Patient Awareness Events

Penumbra, Inc. (NYSE:PEN), a global interventional therapies company, today announced a series of events in New York City aimed to raise awareness for stroke treatment, coinciding with the one-year anniversary of the...

Randomized Penumbra 3D Trial Of Next Generation Stent Retriever Meets Primary Endpoints

Randomized Penumbra 3D Trial Of Next Generation Stent Retriever Meets Primary Endpoints

Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy of...

Penumbra Announces Key Events At Society Of NeuroInterventional Surgery 2016 Meeting

Penumbra Announces Key Events At Society Of NeuroInterventional Surgery 2016 Meeting

Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced its schedule of key events at the Society of NeuroInterventional Surgery (SNIS) 13 th Annual Meeting to be held July 25-28...

Penumbra To Launch LanternTM Microcatheter, Present Final Results Of Multicenter Prism Trial On Indigo® System At SIR 2016

Penumbra To Launch LanternTM Microcatheter, Present Final Results Of Multicenter Prism Trial On Indigo® System At SIR 2016

Penumbra, Inc., a global interventional therapies company, today announced the launch of its Lantern ™ microcatheter at the upcoming Society for Interventional Radiology 2016 meeting (SIR 2016) to be held at the...

TheStreet Quant Rating: C (Hold)